PRKCD and neoplasm: Knockout of PKCδ repressed DLBCL cell proliferation, facilitated cell cycle arrest in the G2/M phase, induced apoptosis in vitro, and inhibited tumor growth in vivo, and enhanced sensitivity to rituximab and chemotherapeutics.